Information Concerning Endocrine Therapy and Adherence of Patients with Breast and Prostate Cancer

Linke, Bettina; Liebl, Patrick; Marten, D.; Stoll, C; Jung, Byoungsok; Wuensch, Peter H.; Huebner, Jutta

doi:10.1016/j.clon.2015.03.002

Cited by 7 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have shown that UA has a molecular inhibitory effect on oncogenic proliferative pathways by regulating related genes and miRNA expressions, apoptosis and cell cycle regulators and the proteins involved in invasive processes on many cancer cells. Tam and/or Enz can regulate cell death by inhibiting hormone receptor activity, ER and AR, in BC and PC cells . Thus, our findings showed that the combination of UA and hormone therapy drugs was more potent than UA and Tam or Enz alone.…”

Section: Discussionmentioning

confidence: 61%

“…Since almost all of the newly diagnosed PC and a large proportion of BC are hormone‐dependent, hormone therapy is an important treatment option for BC and PC. The main goal of this therapy is (a) to block the synthesis of the relevant hormone: estrogen in BC and androgen in PC or (b) to destroy the activity of the related hormone receptor: estrogen receptor (ER) in BC and androgen receptor (AR) in PC . The selective ER modulator Tamoxifen (Tam) is the most commonly used anticancer drug in the premenopausal period in patients with ER+ BC .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor‐positive breast and prostate cancer cells

Eskiler

Eryılmaz

Yurdacan

et al. 2019

J Biochem & Molecular Tox

View full text Add to dashboard Cite

The aim of this study was to investigate the combined effects of usnic acid (UA) and Tamoxifen (Tam) or Enzalutamide (Enz) on hormone receptor‐positive breast and prostate cancer (BC and PC), respectively. The antiproliferative and apoptotic effects of Tam or Enz alone and in combination with UA on MCF7 and LNCaP cancer cells were detected. The results of the WST‐1 assay indicated that UA was a promising anticancer compound that significantly enhanced the effectiveness of hormone therapy drugs compared with each drug alone (combination index < 1). In addition, the combination of UA with Tam or Enz remarkably induced more cell cycle arrest at the G0/G1 phase and apoptosis than only drug‐treated cells (P < 0.01). Consequently, our findings suggest that the combination of UA with Tam or Enz may be a potential therapeutic approach for the treatment of BC and PC and further studies are required to exploit the potential mechanisms of synergistic effects.

show abstract

Section: Discussionmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor‐positive breast and prostate cancer cells

Eskiler

Eryılmaz

Yurdacan

et al. 2019

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…Females more often use CAM because physicians providing CAM listen more intensely to them. This may be due to more needs of communication from the part of the women or it may be that male patients get more information from their physicians than females [19]. In another study, we were able to show that men were more satisfied with information regarding endocrine therapy provided by the physician than women.…”

Section: Discussionmentioning

confidence: 83%

Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care

Wortmann

Bremer²,

Eich

et al. 2016

Med Oncol

Self Cite

View full text Add to dashboard Cite

Complementary and alternative medicine (CAM) is widely used by cancer patients. In order to learn more on the usage of CAM, its reasons and motifs as well as sources of information along the trajectory of treatment, we decided to evaluate the prevalence and predictors for the use of CAM by cancer patients while being under active treatment with chemo- or radiotherapy or in aftercare. We distributed a standardized questionnaire among patients attending a department of radio-oncology, an ambulance for oncology and offices of general practitioners (GPs). Five hundred and six patients took part. Most attributed cancer to stress and trauma (23.7 and 16.4 %) or genes (20.8 %). Forty-four percentage reported knowing a physician with competence in CAM, and in all settings, most patients named the GP. Fifty-one percentage admitted using CAM, 35 % informed the oncologist about using CAM, 56 % informed the GP, and 26 % did not inform any physician. Most often used CAM was vitamin D (17 %) and selenium (16 %). Most important goals were to strengthen the immune system (59 %) and become active (52 %). Most patients were satisfied with the CAM methods they used. Yet, with some methods, dissatisfaction was up to 30 %. The GP has an important function concerning CAM in oncology as most patients believe the GP to have best knowledge in CAM. In order to integrate complementary medicine into evidence-based medicine, physicians should be trained on how to communicate on CAM with the patient and with each other. Explaining cancer and cancer therapies in a way lay persons are able to understand may be helpful. Physicians should actively address patients' needs of involvement not only in decision making, but also actively in the therapy.

show abstract

“…While 70% of breast cancers are hormone sensitive and expressed ER, almost all of the prostate cancers are AR positive and androgen dependent at time of diagnosis . The main therapeutic strategy for these cancer types are similar and are called “endocrine or hormone therapy” targeting to block related hormone synthesis or hormone receptor activity . Although hormone therapy gives effective results at the beginning of treatment, acquired therapy resistance is known to develop in later period .…”

Section: Introductionmentioning

confidence: 99%

In vitro cytotoxic and antiproliferative effects of usnic acid on hormone‐dependent breast and prostate cancer cells

Eryılmaz

Eskiler

Egelí

et al. 2018

J Biochem & Molecular Tox

View full text Add to dashboard Cite

The aim of the current study was first to investigate cytotoxic activity of usnic acid (UA) on hormone-dependent breast and prostate cancer, and normal cells. Cells were treated with increasing concentrations (25 to 150 µM) of UA for 48 hours and cell viability, quantitative and morphological analysis of cell death, and cell cycle analysis were performed. UA was shown to have selective cytotoxicity on hormone-dependent cancer cells with the IC levels of 71.4 and 77.5 µM for MCF7 and LNCaP cells, respectively. UA induced apoptotic cell death and G0/G1 cell cycle arrest without damaging normal cells. MCF7 cells were more sensitive to UA than LNCaP cells. Our results first revealed that UA is a promising candidate as an alternative agent for hormone-dependent breast and prostate cancers. However, molecular mechanism underlying the UA-mediated cell death in cancer cells should be investigated further.

show abstract

Information Concerning Endocrine Therapy and Adherence of Patients with Breast and Prostate Cancer

Cited by 7 publications

References 3 publications

Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor‐positive breast and prostate cancer cells

Synergistic effects of hormone therapy drugs and usnic acid on hormone receptor‐positive breast and prostate cancer cells

Use of complementary and alternative medicine by patients with cancer: a cross-sectional study at different points of cancer care

In vitro cytotoxic and antiproliferative effects of usnic acid on hormone‐dependent breast and prostate cancer cells

Contact Info

Product

Resources

About